InsiderTrades.com logo
Pentagon contract could send this $2 AI stock soaring
From Behind the Markets   |   Ad
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
Get all the info here >>>
Anna Trask net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anna Trask Biography and Net Worth

Insider of Decibel Therapeutics
Anna Trask joined Decibel as chief people, community and culture officer in January 2018, bringing with her nearly 30 years of experience in the field of human resources. Prior to Decibel, Anna served as senior director, human resources at the Dana-Farber Cancer Institute, as chief human resource officer at Boston Medical Center Healthnet Plan and in leadership positions at Neighborhood Health Plan, Pine Manor College and Harvard Pilgrim Health Care/Harvard Community Health Plan. Across these roles, she was responsible for creating and implementing innovative organizational design and development programs to improve critical areas such as transparency, efficiency and effectiveness; professional development and organizational diversity. Anna graduated with a B.A. in politics from Mount Holyoke College and has a master’s degree in psychology from Boston University.

How old is Anna Trask?

Ms. Trask is currently 65 years old. There are 4 older executives and no younger executives at Decibel Therapeutics. The oldest executive at Decibel Therapeutics is Dr. Albert S. B. Edge, Co-Founder & Member of Scientific Advisory Board, who is 68 years old. Learn More on Anna Trask's age.

How do I contact Anna Trask?

The corporate mailing address for Ms. Trask and other Decibel Therapeutics executives is 1325 Boylston Street Suite 500, Boston MA, 02215. Decibel Therapeutics can also be reached via phone at 617-370-8701 and via email at [email protected]. Learn More on Anna Trask's contact information.

Has Anna Trask been buying or selling shares of Decibel Therapeutics?

Anna Trask has not been actively trading shares of Decibel Therapeutics within the last three months. Most recently, Anna Trask sold 5,291 shares of the business's stock in a transaction on Thursday, December 2nd. The shares were sold at an average price of $6.37, for a transaction totalling $33,703.67. Learn More on Anna Trask's trading history.

Who are Decibel Therapeutics' active insiders?

Decibel Therapeutics' insider roster includes Laurence Reid (Insider), and Anna Trask (Insider). Learn More on Decibel Therapeutics' active insiders.

Anna Trask Insider Trading History at Decibel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2021Sell5,291$6.37$33,703.67View SEC Filing Icon  
11/3/2021Sell378$8.34$3,152.52View SEC Filing Icon  
10/14/2021Sell5,364$7.55$40,498.20View SEC Filing Icon  
See Full Table

Anna Trask Buying and Selling Activity at Decibel Therapeutics

This chart shows Anna Trask's buying and selling at Decibel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Decibel Therapeutics Company Overview

Decibel Therapeutics logo
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Read More

Today's Range

Now: $4.91
Low: $4.90
High: $5.11

50 Day Range

MA: $5.00
Low: $4.91
High: $5.23

2 Week Range

Now: $4.91
Low: $1.61
High: $5.40

Volume

1,261,100 shs

Average Volume

122,002 shs

Market Capitalization

$123.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Pentagon contract could send this $2 AI stock soaring
From Behind the Markets   |   Ad
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
Get all the info here >>>